We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+16.34%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
+$94.4M
(+3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-5.13%
Top 10 Holdings %
Top 10 Hldgs %
44.17%
Holding
70
New
30
Increased
7
Reduced
17
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maravai LifeSciences
MRVI
|
+$87.3M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$79.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$72.1M |
| 4 |
HOLX
Hologic
HOLX
|
+$71.8M |
| 5 |
McKesson
MCK
|
+$70.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$113M |
| 2 |
Zimmer Biomet
ZBH
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$107M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$93.1M |
| 5 |
Medtronic
MDT
|
+$87.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.87% |
| 2 | Real Estate | 3.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $155M | 5.98% |
2,118,090
+327,780
| +18% | +$24.4M |
|
2
IQVIA
IQV
$39.1B
| $144M | 5.55% |
803,310
-37,430
| -4% | -$6.31M |
|
3
Vertex Pharmaceuticals
VRTX
$122B
| $138M | 5.32% |
583,290
+220,900
| +61% | +$50.7M |
|
4
Cooper Companies
COO
$14.2B
| $126M | 4.84% |
1,382,520
+416,360
| +43% | +$35.7M |
|
5
HCA Healthcare
HCA
$85.7B
| $117M | 4.51% |
711,240
-215,070
| -23% | -$31.4M |
|
6
Madrigal Pharmaceuticals
MDGL
$11.4B
| $100M | 3.87% |
902,601
-227,347
| -20% | -$27.8M |
|
7
Aurinia Pharmaceuticals
AUPH
$1.93B
| $95.9M | 3.7% |
6,937,448
-1,936,505
| -22% | -$28.2M |
|
8
AbbVie
ABBV
$455B
| $91.5M | 3.53% |
853,650
-465,250
| -35% | -$44.7M |
|
9
Humana
HUM
$44B
| $90.3M | 3.48% |
220,181
-8,749
| -4% | -$3.64M |
|
|
10
Maravai LifeSciences
MRVI
$996M
| $87.9M | 3.39% |
+3,134,712
| New | +$87.3M |
|
|
11
Zimmer Biomet
ZBH
$18.4B
| $85M | 3.28% |
567,926
-777,429
| -58% | -$110M |
|
|
12
Bio-Rad Laboratories Class A
BIO
$8.74B
| $81.7M | 3.15% |
+140,080
| New | +$79.8M |
|
|
13
Bristol-Myers Squibb
BMY
$132B
| $80.5M | 3.1% |
1,297,700
+1,172,200
| +934% | +$72.1M |
|
|
HOLX
14
DELISTED
Hologic
HOLX
| $74.1M | 2.86% |
+1,017,280
| New | +$71.8M |
|
|
15
McKesson
MCK
$101B
| $73.5M | 2.84% |
+422,800
| New | +$70.4M |
|
|
16
Medtronic
MDT
$110B
| $70.8M | 2.73% |
604,150
-798,010
| -57% | -$87.8M |
|
17
Guardant Health
GH
$20.2B
| $70M | 2.7% |
543,160
-254,570
| -32% | -$29.3M |
|
18
Johnson & Johnson
JNJ
$617B
| $68.5M | 2.64% |
+435,010
| New | +$64.2M |
|
19
Haemonetics
HAE
$3.85B
| $67.3M | 2.59% |
+566,370
| New | +$61M |
|
20
Royalty Pharma
RPRX
$26.2B
| $67M | 2.59% |
1,339,530
-156,880
| -10% | -$6.66M |
|
|
21
UnitedHealth
UNH
$383B
| $61.4M | 2.37% |
174,990
-336,380
| -66% | -$113M |
|
|
SYNH
22
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $54M | 2.08% |
+793,320
| New | +$49.5M |
|
23
PUT
Invesco QQQ Trust
QQQ
$450B
| $43.9M | 1.69% |
+140,000
| New | +$41.1M |
|
24
Agios Pharmaceuticals
AGIO
$1.95B
| $43.2M | 1.67% |
+997,070
| New | +$39.4M |
|
25
LivaNova
LIVN
$4.45B
| $40.8M | 1.57% |
+616,030
| New | +$34.3M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2020 Portfolio in Review
As of Q4 2020, HealthCor Management held 70 positions worth $2.59B, up 3.8% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
HealthCor Management withdrew a net $133M in Q4 2020, closing 16 positions and reducing 17 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $107M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Real Estate.
Against the trend, HealthCor Management opened a new position in Maravai LifeSciences worth $87.9M.
- HealthCor Management's largest Q4 2020 buy was Maravai LifeSciences: 3,134,712 shares worth $87.9M.
- HealthCor Management added most to Bristol-Myers Squibb in Q4 2020, an estimated $72.1M increase.
- HealthCor Management's biggest Q4 2020 reduction was UnitedHealth, cutting an estimated $113M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q4 2020, selling an estimated $107M.
- HealthCor Management's ten largest holdings make up 44% of its $2.59B portfolio in Q4 2020.
- HealthCor Management opened 30 new positions and closed 16 in Q4 2020.
- HealthCor Management's portfolio value rose 3.8% quarter-over-quarter to $2.59B.
Based on HealthCor Management's 13F filing for Q4 2020, filed 16 Feb 2021.